MoleculeMind: A Leading AI Protein Design Platform from China 111

MoleculeMind is a leading domestic AI protein design platform company, founded by Xu Jinbo, the global pioneer of AI protein folding technology and a computational biologist. It boasts a world-class team of computational biology specialists. Leveraging top-tier AI algorithms, MoleculeMind accelerates protein design and optimization, ushering in a new era of computational biology and reshaping the technological path of life sciences, with the ambition to become "the Merck of the AI era."

Standing at the forefront of a new round of technological and industrial transformation represented by the biotech revolution, MoleculeMind regards artificial intelligence as a powerful tool to transform and even颠覆 life science research. The company is bringing revolutionary changes to protein discovery, optimization, and design through top-tier AI algorithms, accelerating the entire drug development pipeline, and driving innovation across all fields including industrial and agricultural production, materials design, and environmental improvement.

Technical Advantages of MoleculeMind:

• AI Protein Design Technology: MoleculeMind possesses globally leading AI protein design technology, capable of achieving precise protein optimization and design with small or even zero samples.

• MoleculeOS Platform: The MoleculeOS platform features protein structure and property prediction, as well as peptide and protein optimization capabilities, and is one of the core technologies of MoleculeMind.

• NewOrigin Large Model: NewOrigin (Darwin), developed by MoleculeMind, is the world's first industry-grade AI protein generation large model integrating sequence, structure, function, and evolution, capable of customizing protein generation based on specific requirements.

Application Areas of MoleculeMind:

• Biopharmaceuticals: MoleculeMind's technology is applied to the design and development of macromolecular drugs, such as reducing toxicity by hundreds of times while maintaining tumor-inhibiting activity.

• Synthetic Biology: In collaboration with Cathay Biotech, a leading synthetic biology company, AI-designed enzyme protein structures increased strain productivity by 5 times.

• Vaccine Development: In protein vaccine design projects, MoleculeMind performs multi-objective optimization on vaccine stability and expression levels. Animal experiment verification shows that the neutralizing antibody titers produced by the vaccine are several times higher than those of published patents and protein vaccines from major pharmaceutical companies.

Funding History and Partnerships

• Funding: Since its establishment, MoleculeMind has received multiple rounds of investment, including a tens-of-millions-of-dollars angel round and a hundreds-of-millions-of-RMB Series A round. Investors include prominent institutions such as Sequoia Capital China and Baidu Ventures.

• Strategic Partners: The company has established partnerships with national-level life science laboratories and Cathay Biotech, jointly exploring the application of AI protein technology in biopharmaceuticals and synthetic biology.

MoleculeMind's AI technology not only demonstrates potential in drug development—such as designing novel cytokines to reduce toxicity—but is also applied in optimizing plastic-degrading enzymes to enhance their thermal stability, and has achieved remarkable results in vaccine design, surpassing international standards.

Currently, MoleculeMind has reached cooperation with national-level life science laboratories to build a world-class computational biology discipline in China, promoting the industrial-scale transformation of scientific and technological achievements through an integrated approach of production, academia, research, and application. The company has built the proprietary AI macromolecule optimization and design platform "MoleculeOS," which uses data-driven deep learning methods to help biotechnology experts quickly identify and generate the most suitable proteins, rapidly projecting laboratory research results to industrial-scale applications.